Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Quality Lowdown: What Happens When The US FDA Must Choose Between Risks

Executive Summary

Tuberculosis or cancer, sterility assurance or shortages, the choices come at you fast; Takeda, Wintac, Banco Vida updates.

You may also be interested in...



How US FDA Wants Pharmaceutical Production Volumes Reported For Drug Shortage Prevention

Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.

How US FDA Wants Pharmaceutical Production Volumes Reported For Drug Shortage Prevention

Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.

US FDA’s Machine Learning Analysis Suggests Where To Look For Manufacturing Site Quality Problems

XGBoost model sees site complexity contributes to quality risk, but misses device-related issues, says third FDA pharmaceutical quality report.

Related Content

Topics

UsernamePublicRestriction

Register

PS142811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel